NO331251B1 - Faktor VII-polypeptidvariant, nukleinsyrekonstruksjon, rekombinant vertscelle, ikke-humant transgent dyr, fremgangsmate for fremstilling av faktor VII-poly¬peptidet, samt anvendelse av et faktor VII-polypeptid til fremstilling av et medi¬kament for behandling av blodningsepisoder - Google Patents

Faktor VII-polypeptidvariant, nukleinsyrekonstruksjon, rekombinant vertscelle, ikke-humant transgent dyr, fremgangsmate for fremstilling av faktor VII-poly¬peptidet, samt anvendelse av et faktor VII-polypeptid til fremstilling av et medi¬kament for behandling av blodningsepisoder

Info

Publication number
NO331251B1
NO331251B1 NO20031129A NO20031129A NO331251B1 NO 331251 B1 NO331251 B1 NO 331251B1 NO 20031129 A NO20031129 A NO 20031129A NO 20031129 A NO20031129 A NO 20031129A NO 331251 B1 NO331251 B1 NO 331251B1
Authority
NO
Norway
Prior art keywords
factor vii
vii polypeptide
nucleic acid
treatment
drug
Prior art date
Application number
NO20031129A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031129L (no
NO20031129D0 (no
Inventor
Ole Hvilsted Olsen
Egon Persson
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2001/000596 external-priority patent/WO2002022776A2/en
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of NO20031129D0 publication Critical patent/NO20031129D0/no
Publication of NO20031129L publication Critical patent/NO20031129L/no
Publication of NO331251B1 publication Critical patent/NO331251B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20031129A 2000-09-13 2003-03-12 Faktor VII-polypeptidvariant, nukleinsyrekonstruksjon, rekombinant vertscelle, ikke-humant transgent dyr, fremgangsmate for fremstilling av faktor VII-poly¬peptidet, samt anvendelse av et faktor VII-polypeptid til fremstilling av et medi¬kament for behandling av blodningsepisoder NO331251B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001361 2000-09-13
PCT/DK2001/000596 WO2002022776A2 (en) 2000-09-13 2001-09-13 Human coagulation factor vii variants

Publications (3)

Publication Number Publication Date
NO20031129D0 NO20031129D0 (no) 2003-03-12
NO20031129L NO20031129L (no) 2003-05-12
NO331251B1 true NO331251B1 (no) 2011-11-07

Family

ID=8159711

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031129A NO331251B1 (no) 2000-09-13 2003-03-12 Faktor VII-polypeptidvariant, nukleinsyrekonstruksjon, rekombinant vertscelle, ikke-humant transgent dyr, fremgangsmate for fremstilling av faktor VII-poly¬peptidet, samt anvendelse av et faktor VII-polypeptid til fremstilling av et medi¬kament for behandling av blodningsepisoder

Country Status (11)

Country Link
US (3) US7176288B2 (ko)
KR (1) KR100882482B1 (ko)
CN (2) CN100475959C (ko)
BR (1) BR0113854A (ko)
CA (1) CA2420892A1 (ko)
CZ (1) CZ2003611A3 (ko)
ES (1) ES2429523T3 (ko)
MX (1) MXPA03001984A (ko)
NO (1) NO331251B1 (ko)
RU (1) RU2326126C2 (ko)
ZA (1) ZA200301610B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ES2325877T3 (es) 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7173000B2 (en) * 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
EP1499719B1 (en) * 2002-04-30 2010-11-17 Bayer HealthCare LLC FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
WO2004029091A2 (en) * 2002-09-30 2004-04-08 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
ATE431403T1 (de) * 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
RU2373282C2 (ru) * 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
JP2007520530A (ja) * 2004-02-05 2007-07-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 外傷の遅発型合併症の治療のための、ＶＩＩａ因子又はＶＩＩａ因子等価物の使用
ATE469216T1 (de) * 2004-08-17 2010-06-15 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
JP2009543841A (ja) * 2006-07-17 2009-12-10 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
EP2099475B1 (en) * 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
WO2008127702A2 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
EP2014299A1 (en) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
ES2549074T3 (es) 2008-05-30 2015-10-22 Novo Nordisk Health Care Ag Método de control de una reacción de modificación de polipéptidos
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
EP2149603A1 (en) * 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
TWI541252B (zh) 2010-10-26 2016-07-11 韓美科學股份有限公司 因子ｖｉｉ／ｖｉｉａ之量產方法
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
SG11201404885RA (en) 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
JP2015532307A (ja) * 2012-10-15 2015-11-09 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP0521873B1 (en) * 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
WO1994007515A1 (en) 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
ATE210458T1 (de) 1993-05-21 2001-12-15 Zymogenetics Inc Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
ES2195025T3 (es) 1995-12-01 2003-12-01 Genentech Inc Proteinas de fusion de un dominio de factor tisular-dominio de kunitz como inhibidores del factor viia.
JPH1059866A (ja) 1996-08-19 1998-03-03 Chemo Sero Therapeut Res Inst 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
KR100565883B1 (ko) 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 응고 및 종양 치료용 조직 인자 방법 및 조성물
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
US5994296A (en) 1998-03-05 1999-11-30 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
ES2325877T3 (es) 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
WO2001075086A2 (en) 2000-03-31 2001-10-11 Zymogenetics, Inc. Multi-domain proteinase inhibitor
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
AU2001258230A1 (en) 2000-05-10 2001-11-20 Novo-Nordisk A/S Pharmaceutical composition comprising a factor viia and a tfpi inhibitor
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
IL156842A0 (en) 2001-02-05 2004-02-08 Novo Nordisk Healthcare Ag Combined use of factor vii polypeptides and factor ix polypeptides
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2004029090A1 (en) 2002-09-25 2004-04-08 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides

Also Published As

Publication number Publication date
CA2420892A1 (en) 2002-03-21
CZ2003611A3 (cs) 2003-08-13
KR100882482B1 (ko) 2009-02-06
US20030100740A1 (en) 2003-05-29
CN100475959C (zh) 2009-04-08
RU2326126C2 (ru) 2008-06-10
US20060252129A1 (en) 2006-11-09
NO20031129L (no) 2003-05-12
KR20030067669A (ko) 2003-08-14
ES2429523T3 (es) 2013-11-15
CN1630721A (zh) 2005-06-22
NO20031129D0 (no) 2003-03-12
US20030104978A1 (en) 2003-06-05
BR0113854A (pt) 2004-07-06
MXPA03001984A (es) 2003-08-29
US7026524B2 (en) 2006-04-11
CN101486761A (zh) 2009-07-22
US7176288B2 (en) 2007-02-13
US7695935B2 (en) 2010-04-13
ZA200301610B (en) 2003-09-05

Similar Documents

Publication Publication Date Title
NO331251B1 (no) Faktor VII-polypeptidvariant, nukleinsyrekonstruksjon, rekombinant vertscelle, ikke-humant transgent dyr, fremgangsmate for fremstilling av faktor VII-poly¬peptidet, samt anvendelse av et faktor VII-polypeptid til fremstilling av et medi¬kament for behandling av blodningsepisoder
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
BR0212818A (pt) Polipeptìdeo de fator vii, construção de polionucletìdeo, célula hospedeira, animal transgênico, planta transgênica, método para produzir o polipeptìdeo de fator vii composição farmacêutica, uso de um polipeptìdeo de fator vii, e, método para o tratamento de distúrbios do sangramento em um sujeito ou para o aprimoramento do sistema hemostático normal
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
ATE490309T1 (de) Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
WO2003037932A3 (en) Human coagulation factor vii polypeptides
WO2002081490A8 (en) Computer-directed assembly of a polynucleotide encoding a target polypeptide
DE60234716D1 (de) Verfahren zur Herstellung eines doppeltsträngigen Polynukleotids
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
WO2002031134A3 (en) Novel serine protease genes related to dppiv
FI963860A0 (fi) Alfavirus-cDNA-vektorit
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
GB2382580B (en) Fusion protein having enhanced in vivo activity of erythropoietin
WO2006004675A3 (en) Production of tissue factor in plants
ATE547519T1 (de) Gerinnungsfaktor-vii-polypeptide
WO2002055110A3 (en) Methods for treating blood coagulation disorders
HUP0003564A2 (hu) Protein kinázok és alkalmazásuk
EP1402049A4 (en) PRODUCTION OF HIGH LEVELS OF TRANSGENIC FACTOR VIII WITH STUDY STUDY, AND ITS THERAPEUTIC APPLICATIONS
WO2008068428A3 (fr) Utilisation cosmétique de protéines de type chitinase
WO2001054707A3 (de) Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVO NORDISK HEALTH CARE AG, CH

MM1K Lapsed by not paying the annual fees